Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma

被引:0
|
作者
Thomas E. Hutson
Ram Ganapathi
Paul Elson
Tarek Mekhail
Thomas Olencki
G. Thomas Budd
Ronald M. Bukowski
机构
[1] Cleveland Clinic Foundation;,Experimental Therapeutics Program, Taussig Cancer Center
[2] Cleveland Clinic Foundation;,Clinical Pharmacology Laboratory, Taussig Cancer Center
[3] Cleveland Clinic Foundation,Department of Hematology and Medical Oncology, Taussig Cancer Center
来源
Investigational New Drugs | 2004年 / 22卷
关键词
vinorelbine; phase I clinical trial; microtubule poisons; multi-drug resistance (MDR);
D O I
暂无
中图分类号
学科分类号
摘要
The anti-epileptic diphenylhydantoin (DPH; Dilantin®) selectively enhances the in vitro cytotoxicity of vinca microtubule poisons in both parent sensitive and multi-drug resistant (MDR) human tumor cells. The in vivo clinical activity of this combination has not been fully evaluated. Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicities, and preliminary antitumor activity of the combination of intravenous (IV) bolus vinorelbine (VRL) and oral diphenylhydantoin (DPH) in patients (pts) with refractory solid tumors. Methods: Cohorts of 3–6 pts with refractory cancer were treated with escalating doses of weekly IV bolus VRL (I –20.0 mg/m2; II –22.5 mg/m2; III –25.0 mg/m2; IV –27.5 mg/m2; V –30.0 mg/m2; VI –32.5 mg/m2) combined with a fixed oral dose of DPH (400 mg/day) until MTD or progression. During each 35 day cycle, pts received DPH 400 mg/day administered orally on Days −6 to Day +22 and weekly IV bolus infusion of VRL on Days +1, +8, +15, and +22. The cohort treated at the MTD was expanded to further define toxicity. Results: A total of 25 evaluable pts. (9 men; 16 women) were treated with VRL and DPH at dose levels I (n = 5), II (n = 3), III (n = 2), IV (n = 3), V (n = 7) and VI (n = 5) in 5 week cycles over a 16 month period. Dose limiting toxicity occurred at dose level VI (VRL 32.5 mg/m2) and included grade 3 leukopenia (n = 2), grade 3 neutropenia (n = 1) and grade 4 neutropenia (n = 1) occurring within the first cycle of treatment. There were no responses, however 9 pts had stable disease of variable duration (8–56 weeks) and received a median of 2 cycles of treatment (range 2–14). Conclusion: Intravenous bolus administration of VRL and oral administration of a fixed dose of DPH was well tolerated according to the schedule reported here. Although there were no responses, several patients had prolonged disease stabilization. The recommended phase II dose of VRL when used in this combination is 30 mg/m2.
引用
收藏
页码:277 / 284
页数:7
相关论文
共 50 条
  • [31] A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors
    Haeseong Park
    Kerry Williams
    Nikolaos A. Trikalinos
    Sarah Larson
    Benjamin Tan
    Saiama Waqar
    Rama Suresh
    Daniel Morgensztern
    Brian A. Van Tine
    Ramaswamy Govindan
    Jingqin Luo
    A. Craig Lockhart
    Andrea Wang-Gillam
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 337 - 347
  • [32] Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies
    Mekhail, T
    Hutson, TE
    Elson, P
    Budd, GT
    Srkalovic, G
    Olencki, T
    Peereboom, D
    Pelley, R
    Bukowski, RM
    CANCER, 2003, 97 (01) : 170 - 178
  • [33] A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer
    Saridaki, Zacharenia
    Malamos, Nikolaos
    Kourakos, Panagiotis
    Polyzos, Aristides
    Ardavanis, Alexandros
    Androulakis, Nikolaos
    Kalbakis, Kostas
    Vamvakas, Lambros
    Georgoulias, Vassilis
    Mavroudis, Dimitris
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (01) : 35 - 42
  • [34] A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer
    Zacharenia Saridaki
    Nikolaos Malamos
    Panagiotis Kourakos
    Aristides Polyzos
    Alexandros Ardavanis
    Nikolaos Androulakis
    Kostas Kalbakis
    Lambros Vamvakas
    Vassilis Georgoulias
    Dimitris Mavroudis
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 35 - 42
  • [35] Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial
    Roy S. Herbst
    Cathleen Lynch
    Michael Vasconcelles
    Beverly A. Teicher
    Gary Strauss
    Anthony Elias
    Ian Anderson
    Patrick Zacarola
    Nam H. Dang
    Traci Leong
    Ravi Salgia
    Arthur T. Skarin
    Cancer Chemotherapy and Pharmacology, 2001, 48 : 151 - 159
  • [36] Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial
    Herbst, RS
    Lynch, C
    Vasconcelles, M
    Teicher, BA
    Strauss, G
    Elias, A
    Anderson, I
    Zacarola, P
    Dang, NH
    Leong, T
    Salgia, R
    Skarin, AT
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (02) : 151 - 159
  • [37] Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma
    Conroy, T
    Etienne, PL
    Adenis, A
    Wagener, DJT
    Paillot, B
    Francois, E
    Bedenne, L
    Jacob, JH
    Seitz, JF
    Bleiberg, H
    VanPottelsberghe, C
    VanGlabbeke, M
    Delgado, FM
    Merle, S
    Wils, J
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 164 - 170
  • [38] Phase II study of vinorelbine in patients with hormone refractory prostate cancer
    Caty, A
    Oudard, S
    Humblet, Y
    Beauduin, M
    Suc, E
    Gil, T
    Rolland, F
    Houyau, P
    Sun, X
    Montcuquet, P
    Breza, J
    Favreau, E
    Tresca, P
    Chopin, D
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 135 - 135
  • [39] Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies
    Mundt, AJ
    Rotmensch, J
    Waggoner, SE
    Yamada, SD
    Fleming, GF
    GYNECOLOGIC ONCOLOGY, 2004, 92 (03) : 801 - 805
  • [40] Phase I trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies
    Mundt, AJ
    Rotmensch, J
    Waggoner, SE
    Yamada, D
    Langhauser, C
    Fleming, GF
    GYNECOLOGIC ONCOLOGY, 2001, 82 (02) : 333 - 337